Twenty-first Century Drug Discovery an Expanding Landscape /
‘Twenty-first Century Drug Discovery – an Expanding Landscape’ follows on from the author’s previous book ‘The Science and Business of Drug Discovery – Demystifying the Jargon’, published by Springer as a second edition in 2020. While many of the key scientific and commercial features of drug discov...
保存先:
| 第一著者: | |
|---|---|
| 団体著者: | |
| フォーマット: | 電子媒体 eBook |
| 言語: | 英語 |
| 出版事項: |
Cham :
Springer Nature Switzerland : Imprint: Springer,
2025.
|
| 版: | 1st ed. 2025. |
| 主題: | |
| オンライン・アクセス: | https://doi.org/10.1007/978-3-031-93949-5 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-031-93949-5 | ||
| 003 | DE-He213 | ||
| 005 | 20260810170516.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 250618s2025 sz | o |||| 0|eng d | ||
| 020 | |a 9783031939495 |9 978-3-031-93949-5 | ||
| 024 | 7 | |a 10.1007/978-3-031-93949-5 |2 doi | |
| 050 | 4 | |a TP248.13-248.65 | |
| 072 | 7 | |a TCB |2 bicssc | |
| 072 | 7 | |a SCI010000 |2 bisacsh | |
| 072 | 7 | |a TCB |2 thema | |
| 082 | 0 | 4 | |a 660.6 |2 23 |
| 100 | 1 | |a Zanders, Edward D. |e author. |0 (orcid)0000-0003-4323-2007 |1 https://orcid.org/0000-0003-4323-2007 |4 aut |4 http://id.loc.gov/vocabulary/relators/aut | |
| 245 | 1 | 0 | |a Twenty-first Century Drug Discovery |h [electronic resource] : |b an Expanding Landscape / |c by Edward D. Zanders. |
| 250 | |a 1st ed. 2025. | ||
| 264 | 1 | |a Cham : |b Springer Nature Switzerland : |b Imprint: Springer, |c 2025. | |
| 300 | |a 1 online resource (XV, 244 p. 63 illus.). |b 44 illus. in color. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 341 | 0 | |b Table of contents navigation |2 onix | |
| 341 | 0 | |b Single logical reading order |2 onix | |
| 341 | 0 | |b Short alternative textual descriptions |2 onix | |
| 341 | 0 | |b Use of color is not sole means of conveying information |2 onix | |
| 341 | 0 | |b Use of high contrast between text and background color |2 onix | |
| 341 | 0 | |b Next / Previous structural navigation |2 onix | |
| 341 | 0 | |b All non-decorative content supports reading without sight |2 onix | |
| 347 | |a text file |b PDF |2 rda | ||
| 505 | 0 | |a Part I. Current State of Drug Discovery and Development -- Chapter 1. Introduction -- Chapter 2. Overview of Current Drug Discovery and Development -- Chapter 3. Computational Approaches to Drug Discovery -- Part II. Emerging Opportunities -- Chapter 4. Points of Scientific Impact -- Chapter 5. Hunting for Targets -- Chapter 6. Interventions -- Chapter 7. Development and Implementation. | |
| 520 | |a ‘Twenty-first Century Drug Discovery – an Expanding Landscape’ follows on from the author’s previous book ‘The Science and Business of Drug Discovery – Demystifying the Jargon’, published by Springer as a second edition in 2020. While many of the key scientific and commercial features of drug discovery described in the latter are essentially unchanged since publication, the underlying science has advanced rapidly thereby presenting a broad landscape of opportunities for biopharmaceutical discovery in the twenty-first century and beyond. However, these wide-ranging and complex discovery opportunities are difficult to convey in a short period of time. This book overcomes the problem by giving readers time to study the relevant material at their leisure. Starting with a short overview of the current technical and commercial background to drug discovery and development, the book focuses on the discovery of novel targets and therapeutic agents. The latter are no longer just small molecules, but include engineered proteins, microbes and immune cells created as a result of advances in molecular cell biology and computational methods, among others. These discovery activities are presented as part of a group of ‘systems’ under the headings of Genetics, Cell Biology, Microbiome, Immune and Nervous Systems, none of which are mutually exclusive and all of which depend upon lab-based and computational technologies. These technologies are covered in some detail, highlighting in particular, single molecule and cell analysis, selective drug target degradation and machine learning. | ||
| 532 | 8 | |a Accessibility summary: This PDF does not fully comply with PDF/UA standards, but does feature limited screen reader support, described non-text content (images, graphs), bookmarks for easy navigation and searchable, selectable text. Users of assistive technologies may experience difficulty navigating or interpreting content in this document. We recognize the importance of accessibility, and we welcome queries about accessibility for any of our products. If you have a question or an access need, please get in touch with us at accessibilitysupport@springernature.com. | |
| 532 | 8 | |a No reading system accessibility options actively disabled | |
| 532 | 8 | |a Publisher contact for further accessibility information: accessibilitysupport@springernature.com | |
| 588 | |a Print version record. | ||
| 650 | 0 | |a Biotechnology. | |
| 650 | 0 | |a Pharmaceutical chemistry. | |
| 650 | 0 | |a Pharmacology. | |
| 650 | 1 | 4 | |a Biotechnology. |
| 650 | 2 | 4 | |a Pharmaceutics. |
| 650 | 2 | 4 | |a Pharmacology. |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783031939488 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031939501 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031939518 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-031-93949-5 |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 912 | |a ZDB-2-237 | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||
| 950 | |a Focus Bundle Biomedical and Human Health Sciences (SpringerNature-85407) | ||